By Fineline Cube 
Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration with a partner to launch three independently developed drugs—infliximab, trastuzumab, and pertuzumab—in the Turkish market. This strategic move marks a significant milestone in the company’s internationalization efforts, further expanding its global footprint.
Drug Profile and Applications
Infliximab and trastuzumab have already received marketing approval in China. Infliximab is used to treat autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis, while trastuzumab is indicated for the treatment of tumors including breast and stomach cancers. Pertuzumab, when used in combination with trastuzumab, significantly enhances anti-tumor efficacy. Its marketing application was accepted by China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) in October 2024.
Global Expansion and Future Outlook
Since initiating its international business in 2022, Bioray Biopharmaceutical has actively advanced its global布局, establishing collaborations in over 30 countries and regions. To date, the company’s products have been approved for marketing in three overseas countries/regions, and it has successfully completed six overseas GMP inspections, laying a solid foundation for international product launch. Looking ahead, Bioray Biopharmaceutical will continue to drive innovation and accelerate its internationalization process, aiming to provide more high-quality treatment options for patients worldwide.-Fineline Info & Tech